The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

2025 Combined Net Product Revenue & Non-GAAP Operating Income Guidance Alnylam announced today full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM**), GIVLAARI and ...

said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday. Alnylam expects those ...

Alnylam announced full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM), GIVLAARI and OXLUMO of $2.050 billion to $2.250 billion, representing combined full year ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY – Research ... higher-than-expected revenues for its products Onpattro and Amvuttra, exceeding both their estimates ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari ...